If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
105
results.
Updated on
16/02/2026 [07:00:00]
Results 75 to 100 of 105
Absstract of: WO2026006505A1
NSIs with anti-inflammatory activity are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, or an autoimmune or autoinflammatory disease.
Absstract of: WO2026006510A1
NOD-like receptor protein 3 (NLRP3) inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat NRLP3 inflammasome dysregulation associated diseases and conditions, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID-19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.
Absstract of: WO2026006247A1
2-(Piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof are disclosed. The compounds have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof. The compounds may be useful for inhibiting TNF-α activity, TNF-α synthesis, interleukin-6 (IL-6) level, inflammation, or SARS-COV-2 virus. In some aspects, the compounds, or pharmaceutical compositions including the compounds, are administered to a subject a traumatic brain injury (TBI), an inflammatory disorder, a neurodegenerative disease, cancer, a viral infection, or any combination thereof.
Absstract of: US20260000668A1
Provided herein are compositions comprising one or more diphenyl compounds, such as ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-COV-2 virus.
Absstract of: US20260000698A1
Disclosed herein are compounds of formulaor pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.
Absstract of: US20260000752A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
Absstract of: GB2642116A
A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.
Absstract of: TW202440626A
The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.
Absstract of: EP4670725A1
The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.
Absstract of: WO2024177525A2
Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.
Absstract of: WO2025263616A1
Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprises CD8+ T cell epitope. Provided herein is also a bivalent alphavirus replicon vaccine, which is a combination of a first polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and an antigenic peptide and a second polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a CD8+ T cell epitope. The vaccine is useful against virus infection, especially, COVID-19 or SARS-CoV-2 infection, the treatment of a cancer and/or an inflammatory disease.
Absstract of: WO2025262025A1
The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.
Absstract of: WO2025262023A1
The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and/or booster vaccination in a subject.
Absstract of: WO2025262670A1
A method and composition for the simultaneous detection of a protein and a nucleic acid within a single biological sample using proximity ligation of aptamers and quantitative polymerase chain reaction (qPCR) is disclosed. The invention employs two aptamers, each targeting a distinct epitope of the protein of interest, functionalized with primer sites to enable ligation by way of a short DNA linker in the presence of the protein. This ligated construct is then amplified and detected using qPCR. Concurrently, viral RNA is detected in the same reaction using reverse transcription- qPCR (RT-qPCR) with TaqMan probes in a separate fluorescent channel. This dual detection approach is demonstrated with SARS-CoV-2 nucleocapsid protein and RNA and is validated in saliva samples and digital droplet PCR. The invention provides a sensitive, rapid, and specific method for multiplexed molecular diagnostics.
Absstract of: WO2025260223A1
Specifically, the present invention relates to a humanized monoclonal antibody efficiently neutralizing a SARS-CoV-2 variant strain and a use thereof. Six CDR regions of the antibody are as shown in SEQ ID NOs: 1-6; a heavy chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 7; and a light chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 8. By using B-cell culture combined with antibody cloning technology and by means of a cross-reactive antibody screening strategy, a human monoclonal antibody 2F8 with efficient neutralization activity is obtained from a patient having recovered from original SARS-CoV-2 infection. The antibody can effectively resist neutralization escape by the SARS-CoV-2 variant strain and can be used for passive prevention in a population at a high risk of SARS-CoV-2 infection and the treatment of COVID-19.
Absstract of: US2025389719A1
A disease detection system including a platform or cartridge to perform testing using a rapid lateral flow chromatographic immunoassay (LFIA) test intended for the qualitative detection of the disease in a sample, such as collected sputum, disrupted by a digestive enzyme and a detergent to release its content and digest its proteins and other polymeric molecules. A method of the present invention includes treating a sample with a digestive enzyme and a detergent to disrupt the collected sample releasing content and digesting proteins of the sample to form a lysed-digested-extracted sample, applying the lysed-digested-extracted sample to a platform or cartridge, performing a rapid lateral flow chromatographic immunoassay (LFIA) test of the lysed-digested-extracted sample using the platform or cartridge and detecting presence or absence of an analyte of interest from the tested lysed-digested-extracted sample.
Absstract of: US2025387467A1
An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that inhibits or prevents expression of coronavirus envelope (E) protein and/or M protein, a vaccine comprising the recombinant genome and methods of using the vaccine are provided.
Absstract of: US2025387429A1
A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day, and parenteral including nasal sprays and inhalers. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.
Absstract of: US2025387468A1
The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.
Absstract of: UA161685U
Method for obtaining 6-benzyl-3-arylamino-4H-1,2,4-triazine-5-ones with predicted activity against the SARS-CoV-2 virus: where R=OCHF2, NHC6H5, whereby equimolar amounts of 6-benzyl-3-methylsulfanil-4H-1,2,4-triazine-5-one and the corresponding substituted aromatic amine are heated in an oil bath at a temperature of 170 °C for two hours in an argon atmosphere; after cooling, the reaction mixture is ground with propanol-2, the crystalline precipitate is filtered off, washed with propanol-2, dried, and purified by crystallization from ethanol.
Absstract of: UA161684U
Method for obtaining 3-(41-chlorobenzyl)-mercapto-6-(4-R-benzyl)-4H-1,2,4-triazine-5-ones with predicted activity against SARS-CoV-2 virus, in which equimolar amounts of 3-mercapto-6 -(4-R-benzyl)-4H-1,2,4-triazine-5-ones and 4-chlorobenzyl chloride are boiled in dry acetonitrile with stirring in the presence of calcined K2CO3 for three hours, after which the reaction mass is cooled, poured into ice water, the precipitate is filtered, dried, and crystallized from propanol-2.
Absstract of: UA130231C2
The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.
Absstract of: US2025380705A1
Doubly reentrant topology (DRT) is a unique structure. The present invention first validated the outstanding performance of an anti-biofouling artificial surface comprising a superhydrophobic surface; thereon a plurality of microstructures and having a doubly re-entrant topology (DRT) situated atop respective base structures which demonstrates a striking anti-biofouling effect that can prevent viral contamination. Furthermore, the present invention per se features excellent anti-biofouling ability, which may shed light on the applications of pathogen elimination in alleviating the COVID-19 pandemic.
Absstract of: US2025383359A1
Methods and compositions are disclosed for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include an assay protocol for detecting neutralizing antibodies (e.g., IgA) against the virus in the saliva sample. Compositions include a kit including a stabilizing solution for the patient sample (e.g., saliva sample) and may also include conjugated aragonite particle beads for antibody or viral protein capture.
Nº publicación: WO2025255901A1 18/12/2025
Applicant:
GROOVY MEDICINE HANGZHOU CO LTD [CN]
\u9AD8\u7EF4\u533B\u836F\uFF08\u676D\u5DDE\uFF09\u6709\u9650\u516C\u53F8
Absstract of: WO2025255901A1
A use of a S protein or P4HB protein as a target in preparation of a drug for prevention or treatment of coagulopathy associated with SARS-CoV-2 infection. The S protein is the spike protein of SARS-CoV-2 virus, and the P4HB protein is human protein disulfide isomerase. By means of integrated proteomic and bioinformatic study on SARS-CoV-2 interaction networks in endothelial cells, pulmonary cells, and bronchial cells, the S protein is determined as a key contributor to the procoagulant characteristics of viruses, and the S protein plays a critical role in inducing endothelial cell dysfunction. The S protein directly interacts with P4HB by means of an RBM region thereof, and promotes the secretion of P4HB by means of a lysosomal secretion pathway, thereby promoting thrombosis both in vitro and in a mouse model. Genetic or pharmacological targeting of S-P4HB axis can alleviate coagulopathy in a mouse model. The level of P4HB and disulfide bonds of target proteins thereof are significantly altered in the plasma and leukocytes of COVID-19 patients and are closely associated with the disease severity and coagulation correlation of these patients.
BOPI
Electronic site
